What is Ehlers-Danlos syndrome?

CHRISTINA MAXOURIS | November 4, 2019 | 190 views

The group of disorders usually is characterized by fragile tissue and joints and skin that stretch more than they're supposed to. Patients with EDS usually have weaker or less collagen -- the tough protein that helps keep connective tissue strong and flexible, the National Organization for Rare Disorders says. What that means is their skin can often feel "velvety" or "loose" and, the organization said, that often bruises and scars easily. "People with the classical form of Ehlers-Danlos syndrome experience wounds that split open with little bleeding and leave scars that widen over time to create characteristic 'cigarette paper' scars," the National Library of Medicine says. Loose joints in people with EDS also may mean frequent dislocations.

Spotlight

Evolution Global Talent Attraction

We provide elite executive recruitment & headhunting solutions for the Biotech, Biopharma, Life Sciences and related industries. We understand the value of people as an intellectual asset. Talent sourcing, acquisition and retention are essential to the continued success of a company and as such the market for skilled resources within the Life Sciences industries is extremely competitive.

OTHER ARTICLES
MedTech

Top 10 biotech IPOs in 2019

Article | July 16, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MedTech

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | July 20, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
MedTech

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | July 12, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

Evolution Global Talent Attraction

We provide elite executive recruitment & headhunting solutions for the Biotech, Biopharma, Life Sciences and related industries. We understand the value of people as an intellectual asset. Talent sourcing, acquisition and retention are essential to the continued success of a company and as such the market for skilled resources within the Life Sciences industries is extremely competitive.

Related News

Researchers discover highly infectious vehicle for virus transmission among humans

Medical Xpress | August 08, 2018

Researchers have found that a group of viruses that cause severe stomach illness including the one famous for widespread outbreaks on cruise ships gets transmitted to humans through membrane-cloaked "virus clusters" that exacerbate the spread and severity of the disease. Previously, it was believed that these viruses only spread through individual virus particles. The discovery of these clusters, the scientists say, marks a turning point in the understanding of how these viruses spread and why they are so infectious. This preliminary work could lead to the development of more effective antiviral agents than existing treatments that mainly target individual particles. The researchers studied norovirus and rotavirus—hard-to-treat viruses that are the most common cause of stomach illness, or gastroenteritis, and that afflicts millions of people each year. The viruses cause symptoms ranging from diarrhea to abdominal pain and can sometimes result in death, particularly among young children and the elderly.

Read More

Series A Boost for Swedish Biotech’s Sickle Cell Disease Treatment

Labiotech.eu | July 16, 2018

Modus Therapeutics closed SEK 140M (€13.5M) in Series A financing to complete a Phase II study testing its sickle cell disease drug and to prepare for further clinical trials. The financing round was led by HealthCap, a European venture capital firm focused on life science investments, which will contribute SEK 60M (€5.8M). The remaining funds were raised from existing shareholders. Last year, the company raised €3.4M to support the start of the same Phase II trial. Modus Therapeutics, based in Stockholm, focuses on developing treatments for sickle cell disease and malaria.

Read More

Data show Imnovid-based triple therapy PFS benefit in blood cancer

PharmaTimes Media Limited | July 05, 2018

Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone. According to results of the Phase III OPTIMISMM trial, adding Imnovid (pomalidomide) to Velcade (bortezomib) and low-dose dexamethasone significantly extended PFS to 11.2 months compared to 7.10 months for those taking the latter two alone, equating to a reduction in the risk of disease progression or death by 39 percent.

Read More

Researchers discover highly infectious vehicle for virus transmission among humans

Medical Xpress | August 08, 2018

Researchers have found that a group of viruses that cause severe stomach illness including the one famous for widespread outbreaks on cruise ships gets transmitted to humans through membrane-cloaked "virus clusters" that exacerbate the spread and severity of the disease. Previously, it was believed that these viruses only spread through individual virus particles. The discovery of these clusters, the scientists say, marks a turning point in the understanding of how these viruses spread and why they are so infectious. This preliminary work could lead to the development of more effective antiviral agents than existing treatments that mainly target individual particles. The researchers studied norovirus and rotavirus—hard-to-treat viruses that are the most common cause of stomach illness, or gastroenteritis, and that afflicts millions of people each year. The viruses cause symptoms ranging from diarrhea to abdominal pain and can sometimes result in death, particularly among young children and the elderly.

Read More

Series A Boost for Swedish Biotech’s Sickle Cell Disease Treatment

Labiotech.eu | July 16, 2018

Modus Therapeutics closed SEK 140M (€13.5M) in Series A financing to complete a Phase II study testing its sickle cell disease drug and to prepare for further clinical trials. The financing round was led by HealthCap, a European venture capital firm focused on life science investments, which will contribute SEK 60M (€5.8M). The remaining funds were raised from existing shareholders. Last year, the company raised €3.4M to support the start of the same Phase II trial. Modus Therapeutics, based in Stockholm, focuses on developing treatments for sickle cell disease and malaria.

Read More

Data show Imnovid-based triple therapy PFS benefit in blood cancer

PharmaTimes Media Limited | July 05, 2018

Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone. According to results of the Phase III OPTIMISMM trial, adding Imnovid (pomalidomide) to Velcade (bortezomib) and low-dose dexamethasone significantly extended PFS to 11.2 months compared to 7.10 months for those taking the latter two alone, equating to a reduction in the risk of disease progression or death by 39 percent.

Read More

Events